Efficacy and safety of CT-guided microwave ablation for stage I non-small cell lung cancer in elderly patients
Abstract Objective To evaluate the efficacy of MWA for patients aged ≥ 75 years with stage I NSCLC, and to explore the impacts of age and comorbidities on the long-term outcomes. Methods Patients with stage I NSCLC underwent MWA between November 2016 and December 2020 were retrospectively enrolled....
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-08-01
|
| Series: | Cancer Imaging |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40644-025-00925-6 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849234871242719232 |
|---|---|
| author | JinZhao Peng Jing Luo Ling Yang ZhiXin Bie YuanMing Li DongDong Wang XiaoGuang Li |
| author_facet | JinZhao Peng Jing Luo Ling Yang ZhiXin Bie YuanMing Li DongDong Wang XiaoGuang Li |
| author_sort | JinZhao Peng |
| collection | DOAJ |
| description | Abstract Objective To evaluate the efficacy of MWA for patients aged ≥ 75 years with stage I NSCLC, and to explore the impacts of age and comorbidities on the long-term outcomes. Methods Patients with stage I NSCLC underwent MWA between November 2016 and December 2020 were retrospectively enrolled. Patients were stratified into two cohorts: ≥ 75 years and < 75 years. Propensity score matching was implemented to control selection bias. Primary endpoints included overall survival (OS), cancer-specific survival (CSS), and recurrence-free survival (RFS). Secondary endpoints included independent risk factors influencing OS. Results 138 patients were successfully matched, with 69 in each group. The 1-, 3-, and 5-year OS were 95.7%, 82.6%, and 72.8% in patients aged ≥ 75 years, while 97.1%, 89.9%, and 80.3% in younger patients. There was no significant difference (p = 0.212). The 1-, 3-, and 5-year CSS were 100.0% vs. 98.6%, 92.2% vs. 92.6%, and 83.6% vs. 89.2%, respectively. No significant difference was observed (p = 0.661). The 1-, 3-, and 5-year RFS were 82.1% vs. 88.4%, 60.6% vs. 63.3%, and 58.9% vs. 61.6% without significant difference (p = 0.537). The multivariate COX analysis showed age and Charlson comorbidity index (CCI) were not prognostic factors. Idiopathic pulmonary fibrosis (IPF)/chronic obstructive pulmonary disease (COPD) was an independent risk factor (95% CI 1.32–8.24; p = 0.011). Conclusion MWA is an efficacious tool for patients aged ≥ 75 years with NSCLC. There are no significant differences in efficacy compared with younger patients. Age and CCI are not significant factors associated with prognosis, while IPF/COPD is an independent risk factor. |
| format | Article |
| id | doaj-art-8bfd82d00a4c42a8afe909e54ed1049a |
| institution | Kabale University |
| issn | 1470-7330 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | BMC |
| record_format | Article |
| series | Cancer Imaging |
| spelling | doaj-art-8bfd82d00a4c42a8afe909e54ed1049a2025-08-20T04:03:00ZengBMCCancer Imaging1470-73302025-08-0125111210.1186/s40644-025-00925-6Efficacy and safety of CT-guided microwave ablation for stage I non-small cell lung cancer in elderly patientsJinZhao Peng0Jing Luo1Ling Yang2ZhiXin Bie3YuanMing Li4DongDong Wang5XiaoGuang Li6Department of Interventional Oncology, Qingdao Municipal Hospital, University of Health and Rehabilitation SciencesDepartment of Medical Oncology, The Fourth People’s Hospital of Zibo CityDepartment of Interventional Oncology, Qingdao Municipal Hospital, University of Health and Rehabilitation SciencesDepartment of Minimally Invasive Tumor Therapies Center, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical SciencesDepartment of Minimally Invasive Tumor Therapies Center, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical SciencesDepartment of Interventional Oncology, Qingdao Municipal Hospital, University of Health and Rehabilitation SciencesDepartment of Minimally Invasive Tumor Therapies Center, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical SciencesAbstract Objective To evaluate the efficacy of MWA for patients aged ≥ 75 years with stage I NSCLC, and to explore the impacts of age and comorbidities on the long-term outcomes. Methods Patients with stage I NSCLC underwent MWA between November 2016 and December 2020 were retrospectively enrolled. Patients were stratified into two cohorts: ≥ 75 years and < 75 years. Propensity score matching was implemented to control selection bias. Primary endpoints included overall survival (OS), cancer-specific survival (CSS), and recurrence-free survival (RFS). Secondary endpoints included independent risk factors influencing OS. Results 138 patients were successfully matched, with 69 in each group. The 1-, 3-, and 5-year OS were 95.7%, 82.6%, and 72.8% in patients aged ≥ 75 years, while 97.1%, 89.9%, and 80.3% in younger patients. There was no significant difference (p = 0.212). The 1-, 3-, and 5-year CSS were 100.0% vs. 98.6%, 92.2% vs. 92.6%, and 83.6% vs. 89.2%, respectively. No significant difference was observed (p = 0.661). The 1-, 3-, and 5-year RFS were 82.1% vs. 88.4%, 60.6% vs. 63.3%, and 58.9% vs. 61.6% without significant difference (p = 0.537). The multivariate COX analysis showed age and Charlson comorbidity index (CCI) were not prognostic factors. Idiopathic pulmonary fibrosis (IPF)/chronic obstructive pulmonary disease (COPD) was an independent risk factor (95% CI 1.32–8.24; p = 0.011). Conclusion MWA is an efficacious tool for patients aged ≥ 75 years with NSCLC. There are no significant differences in efficacy compared with younger patients. Age and CCI are not significant factors associated with prognosis, while IPF/COPD is an independent risk factor.https://doi.org/10.1186/s40644-025-00925-6ElderlyComorbiditiesMicrowave ablationLung cancer |
| spellingShingle | JinZhao Peng Jing Luo Ling Yang ZhiXin Bie YuanMing Li DongDong Wang XiaoGuang Li Efficacy and safety of CT-guided microwave ablation for stage I non-small cell lung cancer in elderly patients Cancer Imaging Elderly Comorbidities Microwave ablation Lung cancer |
| title | Efficacy and safety of CT-guided microwave ablation for stage I non-small cell lung cancer in elderly patients |
| title_full | Efficacy and safety of CT-guided microwave ablation for stage I non-small cell lung cancer in elderly patients |
| title_fullStr | Efficacy and safety of CT-guided microwave ablation for stage I non-small cell lung cancer in elderly patients |
| title_full_unstemmed | Efficacy and safety of CT-guided microwave ablation for stage I non-small cell lung cancer in elderly patients |
| title_short | Efficacy and safety of CT-guided microwave ablation for stage I non-small cell lung cancer in elderly patients |
| title_sort | efficacy and safety of ct guided microwave ablation for stage i non small cell lung cancer in elderly patients |
| topic | Elderly Comorbidities Microwave ablation Lung cancer |
| url | https://doi.org/10.1186/s40644-025-00925-6 |
| work_keys_str_mv | AT jinzhaopeng efficacyandsafetyofctguidedmicrowaveablationforstageinonsmallcelllungcancerinelderlypatients AT jingluo efficacyandsafetyofctguidedmicrowaveablationforstageinonsmallcelllungcancerinelderlypatients AT lingyang efficacyandsafetyofctguidedmicrowaveablationforstageinonsmallcelllungcancerinelderlypatients AT zhixinbie efficacyandsafetyofctguidedmicrowaveablationforstageinonsmallcelllungcancerinelderlypatients AT yuanmingli efficacyandsafetyofctguidedmicrowaveablationforstageinonsmallcelllungcancerinelderlypatients AT dongdongwang efficacyandsafetyofctguidedmicrowaveablationforstageinonsmallcelllungcancerinelderlypatients AT xiaoguangli efficacyandsafetyofctguidedmicrowaveablationforstageinonsmallcelllungcancerinelderlypatients |